
XtalPi
Drug Discovery & Development
XtalPi is an AI drug discovery company leveraging artificial intelligence, quantum physics, and robotics to accelerate pharmaceutical research.
About XtalPi
XtalPi leverages AI, quantum physics, and automation to speed up drug discovery and materials research.
Mission & Approach
Mission
“Our mission is to democratize access to data-driven discovery tools to accelerate the molecular R&D process.”
AI Approach
AI generative molecular design, active learning for virtual screening, free energy perturbation (FEP) calculations, crystal structure prediction (CSP), physics-based modeling with quantum mechanics
Products & Solutions
XtalCSP
softwareCrystal Structure Prediction software for polymorphic risk assessment
Cloud-based crystal structure prediction platform that performs global search of crystal structures to identify thermodynamically stable crystalline forms. Features intuitive user interface, scalable cloud resources, and ISO/IEC 27001:2013 compliant data security. Completes regular systems in 2-3 weeks and complex systems in 6-8 weeks.
ChemPlus
deviceDesktop Solid Dispenser for automated powder dispensing
Desktop solid dispensing system for automated handling of solid materials in pharmaceutical research. Part of the autonomous laboratory infrastructure for enhanced precision and throughput in chemical execution.
XtalComplete
deviceIntelligent Crystallization Workstation for automated solid-state research
Automated crystallization workstation for solid-state research and polymorph screening. Integrates with XtalPi's computational platforms to enable high-throughput experimental validation of predicted crystal forms.
NeoDispenser
deviceMicro-Powder Dispensing System for precise material handling
Micro-powder dispensing system for precise automated handling of small quantities of solid materials in pharmaceutical research and development workflows.
PatSight
softwarePatent Extraction tool for drug discovery intelligence
Digital chemistry platform tool that allows discovery scientists to extract patent data, supporting competitive intelligence and freedom-to-operate analysis in drug discovery projects.
PepiX
platformPeptide Platform for peptide drug discovery
Specialized platform for peptide drug discovery combining AI and automation capabilities. Supports hit discovery and optimization for peptide-based therapeutics.
XmartChem
deviceIntelligent Synthesis Workstation for automated chemical synthesis
Advanced automated system for chemical synthesis that streamlines experimental processes and increases efficiency and consistency of research activities. Part of the autonomous lab solution for digitized and automated chemistry execution at scale.
XFEP
FlagshipsoftwareHigh Accuracy Free Energy Calculation Tool for binding affinity predictions
Physics-based free energy perturbation technology for computationally predicting protein-ligand binding at an accuracy matching experimental methods. Covers drug design scenarios like binding free energy, scaffold hopping, and protein mutations across various targets with state-of-the-art molecular force field.
XtalGazer
FlagshipplatformSolid State Research Solution for polymorph screening and crystallization
Comprehensive solid-state research platform combining computational chemistry and AI to empower pharmaceutical solid-state research. Includes crystal structure prediction (CSP), solid-state virtual screening, and morphology prediction capabilities for polymorphic risk assessment and stability analysis.
XMolGen
FlagshipsoftwareGenerative Chemistry Tool for AI-driven molecular design
AI compound generation platform that enables exploration of ultra-large chemical space. Covers most molecular design scenarios and generation strategies, allowing discovery scientists to explore novel chemical space and quickly identify promising drug candidates.
Customer Success Stories
Undisclosed research partner
pharma
SARM1 mechanism of action demonstration
Undisclosed pharmaceutical partner
pharma
Novel hit discovery against GPX4 target
Multiple pharmaceutical partners
pharma
Polymorphic risk assessment using crystal structure prediction
Hiring Activity
View Open Roles →Product & Market
Product Stage
launchedPrimary Market
pharmaCompany Details
- Founded
- 2015
- Headquarters
- Cambridge, MA, USA
- Employees
- 1254
- Stage
- public
- Profile last updated
- June 22, 2026
Category
Drug Discovery & DevelopmentWork here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSocial & Media
Follow on
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as employee counts and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.